Phase
Condition
Tourette's Syndrome
Anxiety Disorders
Obsessive-compulsive Disorder
Treatment
Midazolam
Ketamine 50 MG/ML
Ketamine 50 MG/ML Open Label
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Primary diagnosis of obsessive-compulsive disorder
A score of 16 or higher on the Yale-Brown Obsessive Compulsive Scale and ability to provide written informed consent
At least one previous treatment for OCD
Exclusion Criteria Experimental Group:
Any history of current or past psychotic disorder
A manic episode within the preceding three years
Current or unstable remitted substance abuse or dependence except nicotine
Pregnancy or elevated risk of becoming pregnant during study duration (desire to have children) and refusal to utilize a proper method of contraception
Any current severe personality disorder except comorbid anankastic personality disorder
Morbus Raynaud
Inability to follow the study protocol or adhere to operational requirements
Current and unstable suicidality
Unstable hypertension
Untreated hyperthyroidism
Any unstable cardiovascular disease
Untreated disorders severely affecting the HPA-axis (M.Addison, M.Cushing)
Current pharmacological therapy severely affecting the HPA-axis like corticosteroids or ACTH
Exclusion Criteria Treatment as Usual Group:
Any history of current or past psychotic disorder
A manic episode within the preceding three years
Current or unstable remitted substance abuse or dependence except nicotine
Any current severe personality disorder except comorbid anankastic personality disorder
Current and unstable suicidality
Study Design
Study Description
Connect with a study center
Medical University of Vienna, Department of Psychiatry and Psychotherapy
Vienna, 1090
AustriaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.